Results 131 to 140 of about 19,917 (239)

Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Soticlestat (TAK‐935) is a cholesterol 24‐hydroxylase inhibitor. A physiologically‐based pharmacokinetic model has been developed to predict potential soticlestat drug–drug interactions (DDIs) using the Simcyp v20 Population‐based Simulator and verified with data from single‐/multiple‐rising‐dose and clinical DDI studies.
Hongxia Jia   +7 more
wiley   +1 more source

Fusion of the β2‐adrenergic receptor with either Gαs or βarrestin‐2 produces constitutive signaling by each pathway and induces gain‐of‐function in BEAS‐2B cells

open access: yesFASEB BioAdvances, Volume 4, Issue 12, Page 758-774, December 2022., 2022
Abstract The β2AR is a prototypical G protein‐coupled receptor (GPCR) known to orchestrate different cellular responses by the stimulation of specific signaling pathways. The best‐established signaling pathways for the β2AR are the canonical Gs pathway and the alternative β arrestin 2 (βarr2) pathway.
Emilio Y. Lucero‐Garcia Rojas   +4 more
wiley   +1 more source

Disorder driven allosteric control of protein activity

open access: yesCurrent Research in Structural Biology, 2020
Studies of protein allostery increasingly reveal an involvement of the back and forth order-disorder transitions in this mechanism of protein activity regulation.
Wei-Ven Tee   +2 more
doaj  

Computational Studies of Enzymes for C−F Bond Degradation and Functionalization

open access: yesChemPhysChem, EarlyView.
Enzyme‐mediated strategies for C−F bond cleavage offer a promising solution for addressing the environmental challenges posed by the Forever Chemicals. This review discusses how computational approaches – including molecular docking, molecular dynamics, QM/MM, and bioinformatics – enhance the understanding of enzymatic degradation mechanisms, guiding ...
Kendra M. Cunningham   +2 more
wiley   +1 more source

First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its ...
Nassr Nassr   +12 more
wiley   +1 more source

Structural basis for allosteric substrate specificity regulation in anaerobic ribonucleotide reductases [PDF]

open access: bronze, 2002
Derek T. Logan   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy